Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06324968
Status:
RECRUITING
Last Update Posted:
2024-03-22
First Post:
2023-12-19
Brief Title:
Ro60 Expression in Macrophages in Sjogrens Disease
Sponsor:
Centre Hospitalier Universitaire de Nice
Organization:
Centre Hospitalier Universitaire de Nice
Study Overview
Official Title:
Ro60 Expression in Macrophages in Patients With Primary Sjogrens Syndrome
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RoMioSS
Brief Summary:
Context The Ro60 protein associates with YRNAs or RNYs to form the RoRNP complex which regulates RNA surveillance and maturation It is hypothesized that its impairment by nuclear penetration of the anti-Ro60 autoantibodies would deregulate the anti-inflammatory response in monocytesmacrophages MoMp in patients with Sjögrens disease SD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None